Table 2.
CYP3A4 gene expression in a group of HIV, HCV and HIV/HCV co-infected patients.
| Groups |
CYP3A4 Expression (Mean ± SD) |
p Value | Posthoc | |
|---|---|---|---|---|
| HCV+ without HCV therapy | 2.377 ± 1.227 | 0.359 | 1* vs. 3* p > 0.05 1* vs. 2* p > 0.05 2* vs. 3* p > 0.05 |
|
| HIV+ | 3.730 ± 2.696 | |||
| HIV+/HCV+ without HCV therapy | 4.245 ± 4.799 | |||
| HCV+ without HCV therapy | 2.377 ± 1.227 | 0.149 | 1* vs. 4* PEG IFN p > 0.05 1* vs. 4* DAA p > 0.05 |
|
| HCV+ with HCV therapy | Total | 1.637 ± 1.252 | ||
| PEG IFN | 1.174 ± 0.613 | 0.300 | ||
| DAA | 1.968 ± 1.521 | |||
1*, HCV+ without HCV therapy; 2*, HIV+; 3*, HIV+/HCV+ without HCV therapy; 4*, HCV+ with HCV therapy (total); PEG IFN—pegylated interferon; DAA—direct-acting antivirals.